Endothelium-derived bradykinin: implications for angiotensin-converting enzyme-inhibitor therapy

J Cardiovasc Pharmacol. 1993:22 Suppl 5:S31-6.

Abstract

The effects of angiotensin-converting enzyme (ACE) inhibitors on endothelial autacoid formation were determined in human cultured endothelial cells and in endothelium-intact bovine coronary arteries under resting conditions and after stimulation with bradykinin. Incubation of cultured human endothelial cells with moexiprilat or ramiprilat (0.3 microM) caused a maintained increase in resting intracellular calcium [Ca2+]i, which was prevented by the selective B2-receptor antagonist Hoe 140 (0.1 microM). Both ACE inhibitors also significantly enhanced the increase in [Ca2+]i elicited by bradykinin (3 nM). In parallel with their effect on resting [Ca2+]i, moexiprilat and ramiprilat both induced an increase in intracellular cyclic GMP (cGMP). This increase was prevented by Hoe 140 (0.1 microM) and was abolished by NG-nitro-L-arginine (30 microM), indicating a kinin-induced nitric oxide (NO) formation in this response. The elevation in [Ca2+]i also led to an enhanced production of prostacyclin (PGI2), as indicated by an increase in the concentration of 6-keto prostaglandin F1 alpha (PGF1 alpha) in the cell supernatant. Similar effects of the ACE inhibitors on endothelial autacoid production were observed in endothelium-intact bovine coronary arteries. Like bradykinin (30 nM), moexiprilat (0.3 microM) elicited a nearly twofold increase in the cGMP content of these arteries, which was abolished by both NG-nitro-L-arginine and removal of the endothelium. The functional consequences of this ACE inhibitor-induced increase in vascular cGMP were reflected by a distinct relaxation of arteries preconstricted with PGF2 alpha.(ABSTRACT TRUNCATED AT 250 WORDS)

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • 6-Ketoprostaglandin F1 alpha / metabolism
  • Angiotensin-Converting Enzyme Inhibitors / pharmacology*
  • Animals
  • Arginine / analogs & derivatives
  • Arginine / pharmacology
  • Bradykinin / metabolism*
  • Bradykinin / pharmacology
  • Calcium / metabolism
  • Cattle
  • Cells, Cultured
  • Coronary Vessels / drug effects*
  • Coronary Vessels / physiology
  • Cyclic GMP / metabolism
  • Endothelium, Vascular / cytology
  • Endothelium, Vascular / drug effects*
  • Endothelium, Vascular / metabolism
  • Epoprostenol / metabolism
  • Humans
  • Isoquinolines / pharmacology*
  • Nitric Oxide / metabolism
  • Nitroarginine
  • Ramipril / analogs & derivatives*
  • Ramipril / pharmacology
  • Tetrahydroisoquinolines*
  • Umbilical Veins / drug effects
  • Umbilical Veins / metabolism
  • Vasodilation / drug effects

Substances

  • Angiotensin-Converting Enzyme Inhibitors
  • Isoquinolines
  • Tetrahydroisoquinolines
  • Nitroarginine
  • Nitric Oxide
  • 6-Ketoprostaglandin F1 alpha
  • ramiprilat
  • Arginine
  • Epoprostenol
  • Cyclic GMP
  • moexiprilat
  • Ramipril
  • Bradykinin
  • Calcium